Drug General Information (ID: DDIEGOIDJY)
Drug Name			Heparin		Drug Info		Oritavancin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anticoagulants				Glycopeptide Antibiotics
Structure

Mechanism of Heparin-Oritavancin Interaction (Severity Level: Major)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Heparin				Oritavancin
Mechanism		Heparin				Prolong activated partial thromboplastin time test results
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Heparin when combined with Oritavancin

Recommended Action
Management		Use of intravenous unfractionated heparin is contraindicated for 120 hours (5 days) after oritavancin administration. For patients who require aPTT monitoring within 120 hours of oritavancin dosing, a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT monitoring may be considered.

References
1	Product Information. Orbactiv (oritavancin). The Medicines Company, Parsippany, NJ.